Attys Vie To Lead Investor Suit Against AI-Based Drugmaker
Seven legal teams have filed bids to represent a proposed class of investors in artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. in a suit alleging that it hurt investors after announcing...To view the full article, register now.
Already a subscriber? Click here to view full article